Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.

Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs

Abstrait

Understanding Parkinson?s Disease: Unraveling the Complexity of a Neurological Enigma

Viren Morris

Parkinson’s disease (PD) is a complex neurodegenerative disorder characterized by the progressive degeneration of dopaminergic neurons in the substantia nigra region of the brain. This degeneration leads to a range of motor and non-motor symptoms, including tremors, bradykinesia, rigidity, and cognitive impairment. Despite extensive research, the precise etiology of PD remains elusive, involving a combination of genetic and environmental factors. This comprehensive review aims to elucidate the current understanding of the molecular and cellular mechanisms underlying PD pathology, exploring the interplay between genetic mutations, mitochondrial dysfunction, oxidative stress, and inflammation. Accurate diagnosis of PD remains challenging, particularly in the early stages when symptoms may be subtle. We discuss the evolving landscape of diagnostic tools, from clinical assessments to advanced neuroimaging techniques and biomarker discovery. Early and accurate diagnosis is crucial for implementing timely interventions and personalized treatment strategies. The review also addresses the role of emerging technologies, such as artificial intelligence and machine learning, in refining diagnostic precision and predicting disease progression. The treatment landscape for PD has witnessed significant advancements, ranging from traditional pharmacotherapies to innovative neuroprotective and regenerative approaches. Levodopa, the gold standard in PD pharmacotherapy, is discussed in conjunction with adjunct therapies and deep brain stimulation. Additionally, we highlight promising experimental treatments, including gene therapies, stem cell transplantation, and targeted neuroprotective agents, shedding light on their potential to modify disease progression and enhance patient outcomes. The impact of PD extends beyond motor symptoms, encompassing a spectrum of non-motor manifestations that significantly affect patients’ quality of life. This review examines the diverse array of non-motor symptoms, including autonomic dysfunction, sleep disturbances, and psychiatric complications. A comprehensive understanding of these aspects is crucial for holistic patient management and the development of targeted interventions.

Avertissement: Ce résumé a été traduit à l'aide d'outils d'intelligence artificielle et n'a pas encore été examiné ni vérifié.